Past The Numbers: 13 Analysts Talk about Avidity Biosciences Inventory – Avidity Biosciences (NASDAQ:RNA)

Within the final three months, 13 analysts have printed rankings on Avidity Biosciences RNA, providing a various vary of views from bullish to bearish.

The next desk summarizes their latest rankings, shedding gentle on the altering sentiments inside the previous 30 days and evaluating them to the previous months.

Offering deeper insights, analysts have established 12-month worth targets, indicating a median goal of $65.38, together with a excessive estimate of $72.00 and a low estimate of $48.00. This present common displays a rise of 1.05% from the earlier common worth goal of $64.70.

Exploring Analyst Scores: An In-Depth Overview

The standing of Avidity Biosciences amongst monetary consultants turns into clear with an intensive evaluation of latest analyst actions. The abstract beneath outlines key analysts, their latest evaluations, and changes to rankings and worth targets.

| Analyst | Analyst Agency | Motion Taken | Score |Present Value Goal| Prior Value Goal |
|——————–|——————–|—————|—————–|——————–|——————–|
|Joseph Stringer |Needham |Maintains |Purchase | $60.00|$60.00 |
|Andrew Fein |HC Wainwright & Co. |Maintains |Purchase | $72.00|$72.00 |
|Joseph Stringer |Needham |Maintains |Purchase | $60.00|$60.00 |
|Andrew Fein |HC Wainwright & Co. |Maintains |Purchase | $72.00|$72.00 |
|Keay Nakae |Chardan Capital |Maintains |Purchase | $65.00|$65.00 |
|Geoff Meacham |Citigroup |Pronounces |Purchase | $70.00|- |
|Kostas Biliouris |BMO Capital |Pronounces |Outperform | $72.00|- |
|Geoff Meacham |B of A Securities |Lowers |Purchase | $48.00|$51.00 |
|Louise Chen |Scotiabank |Pronounces |Sector Outperform| $70.00|- |
|Gena Wang |Barclays |Lowers |Obese | $57.00|$63.00 |
|Keay Nakae |Chardan Capital |Maintains |Purchase | $65.00|$65.00 |
|Luca Issi |RBC Capital |Maintains |Outperform | $67.00|$67.00 |
|Andrew Fein |HC Wainwright & Co. |Maintains |Purchase | $72.00|$72.00 |

Key Insights:

• Motion Taken: Analysts adapt their suggestions to altering market situations and firm efficiency. Whether or not they ‘Keep’, ‘Elevate’ or ‘Decrease’ their stance, it displays their response to latest developments associated to Avidity Biosciences. This info supplies a snapshot of how analysts understand the present state of the corporate.
• Score: Analyzing traits, analysts provide qualitative evaluations, starting from ‘Outperform’ to ‘Underperform’. These rankings convey expectations for the relative efficiency of Avidity Biosciences in comparison with the broader market.
• Value Targets: Analysts discover the dynamics of worth targets, offering estimates for the longer term worth of Avidity Biosciences’s inventory. This examination reveals shifts in analysts’ expectations over time.

Analyzing these analyst evaluations alongside related monetary metrics can present a complete view of Avidity Biosciences’s market place. Keep knowledgeable and make data-driven selections with the help of our Scores Desk.

Keep updated on Avidity Biosciences analyst rankings.

Unveiling the Story Behind Avidity Biosciences

Avidity Biosciences Inc is a biopharmaceutical firm dedicated to delivering a brand new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates, or AOCs. Firm’s pipeline presently has three packages in doubtlessly registrational scientific trials: DM1, FSHD, and DMD. The segments contains following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Monetary Insights: Avidity Biosciences

Market Capitalization Evaluation: Falling beneath business benchmarks, the corporate’s market capitalization displays a diminished dimension in comparison with friends. This positioning could also be influenced by components resembling development expectations or operational capability.

Income Progress: Over the 3M interval, Avidity Biosciences showcased optimistic efficiency, reaching a income development charge of 35.57% as of 31 December, 2024. This displays a considerable improve within the firm’s top-line earnings. Compared to its business friends, the corporate trails behind with a development charge decrease than the common amongst friends within the Well being Care sector.

Web Margin: Avidity Biosciences’s web margin is beneath business averages, indicating potential challenges in sustaining robust profitability. With a web margin of -3439.52%, the corporate could face hurdles in efficient value administration.

Return on Fairness (ROE): Avidity Biosciences’s ROE stands out, surpassing business averages. With a formidable ROE of -6.98%, the corporate demonstrates efficient use of fairness capital and robust monetary efficiency.

Return on Belongings (ROA): Avidity Biosciences’s ROA lags behind business averages, suggesting challenges in maximizing returns from its belongings. With an ROA of -6.38%, the corporate could face hurdles in reaching optimum monetary efficiency.

Debt Administration: Avidity Biosciences’s debt-to-equity ratio is beneath business norms, indicating a sound monetary construction with a ratio of 0.0.

How Are Analyst Scores Decided?

Benzinga tracks 150 analyst corporations and experiences on their inventory expectations. Analysts sometimes arrive at their conclusions by predicting how a lot cash an organization will make sooner or later, normally the upcoming 5 years, and the way dangerous or predictable that firm’s income streams are.

Analysts attend firm convention calls and conferences, analysis firm monetary statements, and talk with insiders to publish their rankings on shares. Analysts sometimes charge every inventory as soon as per quarter or each time the corporate has a serious replace.

Along with their assessments, some analysts lengthen their insights by providing predictions for key metrics resembling earnings, income, and development estimates. This supplementary info supplies additional steerage for merchants. It’s essential to acknowledge that, regardless of their specialization, analysts are human and might solely present forecasts primarily based on their beliefs.

Which Shares Are Analysts Recommending Now?

Benzinga Edge provides you prompt entry to all main analyst upgrades, downgrades, and worth targets. Kind by accuracy, upside potential, and extra. Click on right here to remain forward of the market.

This text was generated by Benzinga’s automated content material engine and reviewed by an editor.